# US 2013/0253173 A1 · Antibodies That Are Capable of Specifically Binding Tissue Factor Pathway Inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253173 A1
- Document ID: US20130253173A1
- Status: Published application
- Kind: A1
- Application number: 13/780,631
- Filed: 2013-02-28
- Published: 2013-09-26
- Earliest claimed: 2010-06-30
- Assignees: Novo Nordisk A/S
- Applicants: Novo Nordisk A/S
- Inventors: Ida Hilden; Jes Thorn Clausen; Lars Christian Petersen; Brit Binow Soerensen; Helle Heibroch Petersen; Anders Svensson
- Web page: https://patentgrep.com/patent/US20130253173A1

## CPC

- C07K 16/38: against protease inhibitors of peptide structure
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.

## Claims

### Claim 1

An antibody that is capable of specifically binding to an epitope on the C-terminal of full length TFPI, wherein said epitope comprises an amino acid residue selected from the group consisting of Tyr23, Asn24, Ser25, Va126, Ile27, Gly28, Lys29, Arg31, Lys48, Gln49, Leu52 and Lys56 of SEQ ID NO: 27.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein said epitope comprises the amino acid residues corresponding to the Ile27, Lys29 and Arg31 of SEQ ID NO: 27.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein said epitope comprises Tyr23 of SEQ ID NO: 27.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein said epitope comprises Asn24 of SEQ ID NO: 27.

### Claim 5 (depends on 1)

The antibody of claim 1, wherein said epitope comprises Ser25 of SEQ ID NO: 27.

### Claim 6 (depends on 1)

The antibody of claim 1, wherein said epitope comprises Va126 of SEQ ID NO: 27.

### Claim 7 (depends on 1)

The antibody of claim 1, wherein said epitope comprises Gly28 of SEQ ID NO: 27.

### Claim 8 (depends on 1)

The antibody of claim 1, wherein said epitope comprises Lys48 of SEQ ID NO: 27.

### Claim 9 (depends on 1)

The antibody of claim 1, wherein said epitope comprises Leu52 of SEQ ID NO: 27.

### Claim 10 (depends on 1)

The antibody of claim 1, wherein said epitope comprises Lys56 of SEQ ID NO: 27.

### Claim 11 (depends on 1)

The antibody of claim 1, wherein said epitope further comprises Gln49 of SEQ ID NO: 27.

### Claim 12 (depends on 1)

The antibody of claim 1, wherein said epitope comprises Tyr23, Asn24, Ser25, Va126, Gly28, Lys48, Leu52 and Lys56 of SEQ ID NO: 27.

### Claim 13 (depends on 1)

The antibody of claim 1, wherein the heavy chain of said antibody comprises:
a Tyr in the position corresponding to position 33,
a Glu in the position corresponding to position 50 and
a Trp in the position corresponding to position 99.
of SEQ ID NO: 28.

### Claim 14 (depends on 1)

The antibody of claim 1, wherein the light chain of said antibody comprises:
a Glu in the position corresponding to position 50,
a Ser in the position corresponding to position 91,
an Asp in the position corresponding to position 92 and
a Tyr in the position corresponding to position 96
of SEQ ID NO: 29.

### Claim 15 (depends on 1)

The antibody of claim 1, wherein the heavy chain of said antibody comprises:
a Tyr in the position corresponding to position 33,
a Glu in the position corresponding to position 50 and
a Trp in the position corresponding to position 99.
of SEQ ID NO: 28; and wherein the light chain of said antibody comprises:
a Glu in the position corresponding to position 50,
a Ser in the position corresponding to position 91
an Asp in the position corresponding to position 92 and
a Tyr in the position corresponding to position 96
of SEQ ID NO: 29.

### Claim 16 (depends on 1)

The antibody of claim 1, wherein the heavy chain of said antibody comprises:
a Tyr in the position corresponding to position 33 of CDR1,
a Glu in the position corresponding to position 50 of CDR2 and
a Trp in the position corresponding to position 95 of CDR3,
as defined using Kabat numbering.

### Claim 17 (depends on 1)

The antibody of claim 1, wherein the light chain of said antibody comprises:
a Glu in the position corresponding to position 50 of CDR2,
a Ser in the position corresponding to position 91 of CDR3,
an Asp in the position corresponding to position 92 of CDR3 and
a Tyr in the position corresponding to position 96 of CDR3
as defined using Kabat numbering.

### Claim 18 (depends on 16)

The antibody of claim 16, wherein the light chain of said antibody comprises:
a Glu in the position corresponding to position 50 of CDR2,
a Ser in the position corresponding to position 91 of CDR3,
an Asp in the position corresponding to position 92 of CDR3 and
a Tyr in the position corresponding to position 96 of CDR3
as defined using Kabat numbering.

### Claim 19 (depends on 1)

The antibody of claim 1, wherein the light chain of said antibody comprises:
an Asn or a conservative amino acid substitution thereof in the position corresponding to position 28 of CDR1,
an Asp or a conservative amino acid substitution thereof in the position corresponding to position 30 of CDR1,
an Asp or a conservative amino acid substitution thereof in the position corresponding to position 32 of CDR1,
a Glu in the position corresponding to position 50 of CDR2,
a Ser in the position corresponding to position 91 of CDR3,
an Asp in the position corresponding to position 92 of CDR3,
a Leu or a conservative amino acid substitution thereof in the position corresponding to position 94 of CDR3 and
a Tyr in the position corresponding to position 96 of CDR3
as defined using Kabat numbering, and
wherein the heavy chain of said antibody comprises:
a Ser or a conservative amino acid substitution thereof in the position corresponding to position 31 of CDR1,
a Tyr in the position corresponding to position 33 of CDR1,
a Tyr or a conservative amino acid substitution thereof in the position corresponding to position 35 of CDR1,
a Glu in the position corresponding to position 50 of CDR2,
an Asn or a conservative amino acid substitution thereof in the position corresponding to position 58 of CDR2,
a Trp in the position corresponding to position 95 of CDR3,
an Arg or a conservative amino acid substitution thereof in the position corresponding to position 97 of CDR3 and
a Phe or a conservative amino acid substitution thereof in the position corresponding to position 98 of CDR3
as defined using Kabat numbering.
